An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes

References

• World Health Organization. Global report on diabetes. [ cited 2020 Apr 8]. Available from https://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf?sequence=1
   Google Scholar
• Imperatore G, Boyle JP, Thompson TJ, et al.; SEARCH for Diabetes in Youth Study Group. Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth. Diabetes Care. 2012;35:2515–2520.
   PubMed Web of Science ®Google Scholar
• Miller KM, Foster NC, Beck RW, et al.; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015;38:971–978.
   PubMed Web of Science ®Google Scholar
• McKnight JA, Wild SH, Lamb MJ, et al. Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabet Med. 2015;32:1036–1050.
   PubMed Web of Science ®Google Scholar
• Lu CL, Shen HN, Hu SC, et al. A population-based study of all-cause mortality and cardiovascular disease in association with prior history of hypoglycemia among patients with Type 1 diabetes. Diabetes Care. 2016;39:1571–1578.
   PubMed Web of Science ®Google Scholar
• Purnell JQ, Braffett BH, Zinman B, et al.; DCCT/EDIC Research Group. Impact of excessive weight gain on cardiovascular outcomes in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes Care. 2017;40:1756–1762.
   PubMed Web of Science ®Google Scholar
• Taylor SI, Blau JE, Rother KI, et al. SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks. Lancet Diabetes Endocrinol. 2019;7:949–958.
   PubMed Web of Science ®Google Scholar
• Langford BE, Evans M, Haskins-Coulter T, et al. Systematic literature review and network meta-analysis of sodium-glucose co-transporter inhibitors vs metformin as add-on to insulin in type 1 diabetes. Diabetes Obes Metab. 2020;22:39–50.
   PubMed Web of Science ®Google Scholar
• Patel K, Carbone A. Sodium-glucose cotransporters as potential therapeutic targets in patients with Type 1 diabetes mellitus: an update on phase 3 clinical trial data. Ann Pharmacother. 2019;53:1227–1237.
   PubMed Web of Science ®Google Scholar
• Petrie JR, Chaturvedi N, Ford I, et al.; REMOVAL Study Group. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5:597–609.
   PubMed Web of Science ®Google Scholar
• Garg SK, Moser EG, Bode BW, et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract. 2013;19:19–28.
   PubMed Web of Science ®Google Scholar
• Mathieu C, Zinman B, Hemmingsson JU, et al.; ADJUNCT ONE Investigators. Efficacy and safety of liraglutide added to insulin treatment in Type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care. 2016;39:1702–1710.
   PubMed Web of Science ®Google Scholar
• Dejgaard TF, Frandsen CS, Hansen TS, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2016;4:221–232.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98–S110.
   PubMed Web of Science ®Google Scholar
• Lyons SK, Hermann JM, Miller KM, et al. Use of adjuvant pharmacotherapy in Type 1 diabetes: international comparison of 49,996 Individuals in the prospective diabetes follow-up and T1D exchange registries. Diabetes Care. 2017;40:e139–e140.
   PubMed Web of Science ®Google Scholar
• Forxiga: summary of product characteristics. [ cited 2020 Apr 1]. Available from: https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf
   Google Scholar
• Dandona P, Mathieu C, Phillip M, et al.; DEPICT-1 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled Type 1 diabetes: the DEPICT-1 52-week study. Diabetes Care. 2018;41:2552–2559.
   PubMed Web of Science ®Google Scholar
• Mathieu C, Dandona P, Gillard P, et al.; DEPICT-2 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled Type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial. Diabetes Care. 2018;41:1938–1946.
   PubMed Web of Science ®Google Scholar
• Dandona P, Mathieu C, Phillip M, et al.; DEPICT-1 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:864–876.
   PubMed Web of Science ®Google Scholar
• McCrimmon RJ, Henry RR. SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia. 2018;61:2126–2133.
   PubMed Web of Science ®Google Scholar
• Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012;9:158–169.
   Google Scholar
• Zynquista: summary of product characteristics. [ cited 2020 Apr 1]. Available from: https://www.ema.europa.eu/en/documents/product-information/zynquista-epar-product-information_en.pdf
   Google Scholar
• Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with Type 1 diabetes. N Engl J Med. 2017;377:2337–2348.
   PubMed Web of Science ®Google Scholar
• Buse JB, Garg SK, Rosenstock J, et al. Sotagliflozin in combination with optimized insulin therapy in adults with Type 1 diabetes: the North American inTandem1 study. Diabetes Care. 2018;41:1970–1980.
   PubMed Web of Science ®Google Scholar
• Danne T, Cariou B, Banks P, et al. HbA(1c) and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with Type 1 diabetes: the European inTandem2 study. Diabetes Care. 2018;41:1981–1990.
   PubMed Web of Science ®Google Scholar
• Danne T, Cariou B, Buse JB, et al. Improved time in range and glycemic variability with sotagliflozin in combination with insulin in adults with Type 1 diabetes: a pooled analysis of 24-week continuous glucose monitoring data from the Intandem program. Diabetes Care. 2019;42:919–930.
   PubMed Web of Science ®Google Scholar
• Powell DR, Zambrowicz B, Morrow L, et al. Sotagliflozin decreases postprandial glucose and insulin concentrations by delaying intestinal glucose absorption. J Clin Endocrinol Metab. 2020;105(4):dgz258.
   PubMed Web of Science ®Google Scholar
• van Raalte DH, Bjornstad P, Persson F, et al. The impact of sotagliflozin on renal function, albuminuria, blood pressure, and hematocrit in adults with Type 1 diabetes. Diabetes Care. 2019;42:1921–1929.
   PubMed Web of Science ®Google Scholar
• Henry RR, Thakkar P, Tong C, et al. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with Type 1 diabetes. Diabetes Care. 2015;38:2258–2265.
   PubMed Web of Science ®Google Scholar
• Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1687–1693.
   PubMed Web of Science ®Google Scholar
• Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in Type 1 diabetes. Diabetes Care. 2015;38:1181–1188.
   PubMed Web of Science ®Google Scholar
• Yeh HC, Brown TT, Maruthur N, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med. 2012;157:336–347.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Marquard J, Laffel LM, et al. Empagliflozin as adjunctive to insulin therapy in Type 1 diabetes: the EASE trials. Diabetes Care. 2018;41:2560–2569.
   PubMed Web of Science ®Google Scholar
• Hampp C, Swain RS, Horgan C, et al. Use of sodium-glucose cotransporter 2 inhibitors in patients with Type 1 diabetes and rates of diabetic ketoacidosis. Diabetes Care. 2020;43:90–97.
   PubMed Web of Science ®Google Scholar
• Handelsman Y, Henry RR, Bloomgarden ZT, et al. American association of clinical endocrinologists and american college of endocrinology position statement on the association of Sglt-2 inhibitors and diabetic ketoacidosis. Endocr Pract. 2016;22:753–762.
   PubMed Web of Science ®Google Scholar
• Perkins BA, Rosenstock J, Skyler JS, et al. Exploring patient preferences for adjunct-to-insulin therapy in Type 1 diabetes. Diabetes Care. 2019;42:1716–1723.
   PubMed Web of Science ®Google Scholar
• Weber DR, Haynes K, Leonard MB, et al. Type 1 diabetes is associated with an increased risk of fracture across the life span: a population-based cohort study using The Health Improvement Network (THIN). Diabetes Care. 2015;38:1913–1920.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. CANVAS program collaborative group. canagliflozin and cardiovascular and renal events in Type 2 diabetes. N Engl J Med. 2017;377:644–657.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al.; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2019;380:347–357.
   PubMed Web of Science ®Google Scholar
• Erythropoulou-Kaltsidou A, Polychronopoulos G, Tziomalos K. Sodium-glucose co-transporter 2 inhibitors and fracture risk. Diabetes Ther. 2020;11:7–14.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency: Zynquista Assessment Report. [ cited 2020 Apr 1]. Available from: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zynquista_en.pdf
   Google Scholar